RBC Capital Maintains Outperform on ACADIA Pharmaceuticals, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) but lowers the price target from $29 to $26.
August 07, 2024 | 3:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RBC Capital analyst Gregory Renza maintains an Outperform rating on ACADIA Pharmaceuticals but lowers the price target from $29 to $26.
The Outperform rating suggests continued confidence in ACADIA Pharmaceuticals' performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100